First-in-class anti-TSHR antibody for autoimmune thyroid diseases
Yarrow Bioscience is a clinical-stage biotechnology company developing a first-in-class anti-TSHR antibody (YB-101/GS-098) targeting Graves' disease and thyroid eye disease. Signed $1.37B licensing with GenSci; reverse merger with Vyne Dec 2025.
Create a free account to see funding visualizations and detailed round data.
Create Free AccountDec 2025
Create a free account to see which investors have funded this company.
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
Global clinical research organization specializing in early-stage clinical trials and bioanalytic...
Healthcare company applying technology to drug development by building nimble biotech subsidiarie...
Neuralink is building a brain-computer interface for medical needs and greater human potential.
